# UBS Group

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/ubs-group
Canonical HTML page: https://getyourbrief.com/entity/ubs-group

## Timeline

- **2026-08-22**: Wall Street Zen issues opposing ratings — Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
- **2026-08-14**: Dividend Payment Date — Quarterly dividend paid to shareholders of record July 24.
- **2026-08-12**: T1 Energy earnings and BTIG target move — T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
- **2026-08-10**: Truist raises SM Energy target — Increased price target from $37.00 to $43.00 and maintained a Buy rating.
- **2026-08-05**: SM Energy quarterly results — SM Energy reported $2.19 earnings per share for the quarter.
- **2026-07-24**: Dividend Record Date — Shareholders of record qualify for $0.77 quarterly dividend.
- **2026-07-22**: Q2 Earnings Release — Kaiser Aluminum reports EPS $5.53, beats estimates by $2.87; revenue $1.26B surpasses $1.12B estimate.
- **2026-07-21**: Two updates on SM Energy — Susquehanna lifted its SM target from $31 to $32 (Neutral); Raymond James lowered its target from $55 to $48 (Outperform).
- **2026-07-16**: JPMorgan Cuts Target; Stock Jumps — JPMorgan reduced its PG price target from $164 to $162 with an Overweight rating; P&G declared a $1.0885 dividend and the stock rose 2.3% on cost‑cut news.
- **2026-07-14**: UBS initiates SM Energy — Started coverage with a Buy rating and a $36.00 target price.
- **2026-07-10**: Bank of America Revises Down — Bank of America lowered its PG price objective from $170 to $166, keeping a Buy rating.
- **2026-07-09**: Wells Fargo Reaffirms Underweight — Wells Fargo reiterates underweight rating, sets $158 price target.
- **2026-07-08**: UBS Lifts Price Target — UBS raises Kaiser Aluminum target to $179 from $176, maintains neutral rating.
- **2026-07-08**: Weiss Ratings reaffirms T1 Energy sell — Reaffirmed a Sell (D-) rating on T1 Energy.
- **2026-06-30**: Schikan sells 30,712 shares — Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.

## Recent coverage (20 stories, network-wide)

### T1 Energy Cut to Strong Sell at $4.45; SM Energy Upgraded to Strong Buy
2026-08-24 03:19:53 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Full story: https://getfinancebrief.com/story/t1-energy-strong-sell-sm-energy-strong-buy-wall-street-zen-2026-08

### MUFG Cuts Nike 22.3% to $19.95M, Zoetis 6.4% to $15.38M
2026-08-17 01:14:54 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mitsubishi UFJ's Q2 13F shows a 22.3% reduction in Nike and 6.4% in Zoetis, just as sell-side targets on NKE cluster at $42–$47. For finance professionals, the filings highlight institutional rebalancing, ownership concentration, and analyst caution as key sentiment signals.
Full story: https://getfinancebrief.com/story/mufg-cuts-nike-zoetis-13f-holdings

### Morgan Stanley Cuts AMH PT to $38, Sees 11% Upside in SFR
2026-08-16 15:04:23 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Single-family rental REIT American Homes 4 Rent has a modestly reduced $38 price target from Morgan Stanley, still above a $36.78 consensus and leaving 11% upside. The maintained Overweight rating reinforces the resilience of the SFR asset class amid housing supply constraints.
Full story: https://getproptechbrief.com/story/morgan-stanley-amh-38-proptech-sfr

### Morgan Stanley Cuts AMH PT to $38; Consensus $36.78, 11% Upside
2026-08-16 15:04:14 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Full story: https://getfinancebrief.com/story/morgan-stanley-amh-price-target-38-finance

### VRRM Gaps Down 12% After Earnings Beat—8 Analysts Say Hold or Sell
2026-08-12 14:47:04 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Verra Mobility shares plunged 12% on August 8, 2026, despite beating Q2 earnings estimates. Analyst consensus is 'Reduce' with a $7 target, while Vistance Networks also gapped down amid mixed signals including a $5 dividend and institutional buying.
Full story: https://getfinancebrief.com/story/verra-mobility-vrrn-gap-down-august-2026

### SoFi Stock Surges 3.7% to $18.70 Despite 5 Analyst Target Cuts – What’s Next?
2026-08-12 13:34:09 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SoFi Technologies shares jumped 3.7% on August 4, 2026, even as multiple analysts slashed price targets, creating a tension between market momentum and cautious research. With a PE of 38.96, beta of 2.17, and consensus Hold rating, the fintech’s next move hinges on whether profitability can catch up with valuation.
Full story: https://getfinancebrief.com/story/sofi-stock-surges-3-7-percent-analyst-target-cuts

### HALO stock hits $103 as FY2026 EPS guidance of $8.65-$9.00 overshoots consensus by $0.63
2026-08-12 02:50:02 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Full story: https://getfinancebrief.com/story/halozyme-fy2026-earnings-guidance-beat-stock-surge

### Halozyme's ENHANZE drives 47.7% revenue surge and FY26 EPS guidance 8% above Street
2026-08-12 02:48:54 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Full story: https://getbiobrief.com/story/halozyme-enhanze-partner-royalties-q2-2026-guidance

### CBRE Ups FY2026 EPS View to $7.80-$7.90 as Real Estate Tech Demand Booms
2026-08-05 14:17:03 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CBRE Group's above-consensus EPS guidance underscores the commercial real estate sector's momentum, driven by technology-driven services. For PropTech startups and investors, it signals growing client spending on smart buildings, data analytics, and digital brokerage platforms.
Full story: https://getproptechbrief.com/story/cbre-fy2026-guidance-proptech

### Teva's $1.91-$2.11 EPS Guidance Misses Consensus, Testing Pharma Resilience
2026-08-05 14:16:51 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Full story: https://gethealthbrief.com/story/teva-fy2026-guidance-health

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### Nayax Gaps Up 4.7% as Retail Payment Tech Draws $2.47B Valuation
2026-08-03 06:28:41 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Nayax shares jumped 4.7% on Monday after a series of analyst upgrades, despite a Q1 earnings miss. With a market cap of $2.47 billion and a rich P/E of 85, the cashless payment provider for unattended retail faces both secular tailwinds and profitability scrutiny. Consensus price target stands at $78.16, offering 15.9% upside.
Full story: https://getretailbrief.com/story/nayax-gap-up-retail-payments-valuation

### TeraWulf (WULF) Surges 7% as Bitcoin Mining Stock Targets Hit $40
2026-08-03 06:28:30 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 2

TeraWulf Inc. surged 7% on Monday to $19.43 after multiple analyst upgrades, even after a massive Q1 EPS miss. With a $9.45 billion market cap and a sky-high debt-to-equity ratio of 33, the Bitcoin miner’s stock is a pure play on crypto momentum, as consensus targets reach $34.60 and one analyst calls for $40.
Full story: https://getcryptobrief.com/story/terawulf-wulf-surge-crypto-mining-stocks

### Kaiser Aluminum EPS Beat by $2.87: Revenue Hits $1.26B, Shares Dip to $164.32
2026-07-23 00:53:05 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kaiser Aluminum's Q2 2026 EPS of $5.53 blasts past estimates by 108%, with revenue reaching $1.26B. Despite the beat, the stock slipped 0.03% to $164.32 amid insider sales and mixed analyst targets. The $0.77 quarterly dividend and strong liquidity ratios offer some reassurance.
Full story: https://getfinancebrief.com/story/kaiser-aluminum-earnings-beat-eps-287-revenue-126b

### MCRI Beats Q2 EPS by $0.11; $2.21B Casino Stock Eyes $144 Target Amid Insider Sale
2026-07-21 01:35:47 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Monarch Casino & Resort posted a second-quarter earnings beat of $0.11 per share on revenue strength, driving the stock up 1.1% to $124.38. Valuation metrics remain solid with a P/E of 21.08 and a 1% dividend yield, but a recent CEO stock sale and mixed analyst ratings signal a cautious bias. Truist’s $144 price target offers the most bullish outlook, while Stifel sits at $102.
Full story: https://getfinancebrief.com/story/mcri-earnings-beat-011-eps-analyst-targets-insider-sale

### P&G Stock Climbs 2.3% as 7,000 Job Cuts Signal Retail Margin Push
2026-07-17 19:36:54 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Procter & Gamble shares rose 2.3% on news of 7,000 non‑manufacturing job cuts aimed at boosting margins, alongside a brand‑boosting Head & Shoulders partnership with USA Gymnastics. The move highlights how cost efficiency and brand marketing are driving retail‑sector confidence.
Full story: https://getretailbrief.com/story/pg-stock-retail-margin-push-7000-job-cuts

### P&G Up 2.3% as Analysts Slash Targets but Keep ‘Buy’ Ratings
2026-07-17 19:36:45 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Procter & Gamble gained 2.3% despite multiple analysts lowering price targets, thanks to a solid dividend yield and planned job cuts of up to 7,000. With a moderate buy consensus and an average target of $161.42, value seekers see a 6.6% upside.
Full story: https://getfinancebrief.com/story/pg-stock-up-analyst-target-cuts-buy-ratings

### Morgan Stanley Cuts BlackRock Target to $1,383, Still Sees 34% Upside
2026-07-15 21:49:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Morgan Stanley lowered its BlackRock (BLK) price target to $1,383 while maintaining Overweight, implying a 34% gain. The consensus remains Moderate Buy with an average target of $1,270.72. Diverging analyst revisions signal both caution and opportunity for the asset management giant.
Full story: https://getfinancebrief.com/story/blackrock-price-target-cut-morgan-stanley-1383-upside

### $1.33M Insider Sale at Pharvaris: What It Means for HAE Drug Catalysts
2026-07-11 21:42:38 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Full story: https://getbiobrief.com/story/pharvaris-insider-sale-1.33m-hae-catalysts

### BTIG Sees 108% Upside in McGraw Hill Despite EdTech Reset
2026-06-28 07:38:04 · Sector: edtech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street analyst BTIG reaffirmed a buy rating and $19 target for McGraw Hill (MH), projecting a 107.63% gain from its depressed $9.15 share price. The call highlights deep value in the educational publisher as the entire edtech sector undergoes a post-pandemic correction. With a consensus 'Moderate Buy' and $18.72 target, the stock's extreme undervaluation could reward contrarian edtech investors.
Full story: https://getedtechbrief.com/story/mcgraw-hill-btig-108-percent-upside-edtech

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.